Thus, we hypothesize that drugs such as icatibant that block the B2 receptor or lanadelumab—a monoclonal antibody against HMWK that yields bradykinin, that is also FDA approved for the treatment of angioedema—may represent important avenues that may not only inhibit the inflammatory cascade of the KKS [59,67] but may also inhibit the vasoconstrictor effect of bradykinin. The gene discussed is KNG1; the disease is angioedema.